Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$1.9 - $10.13 $21,812 - $116,292
11,480 New
11,480 $63,000
Q3 2023

Nov 14, 2023

BUY
$29.8 - $40.3 $6.47 Million - $8.75 Million
217,151 New
217,151 $7.54 Million
Q1 2023

May 15, 2023

BUY
$29.51 - $46.65 $12.5 Million - $19.8 Million
423,404 New
423,404 $14.2 Million

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $135M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.